Echolight SpA announces expansion in the Middle East market.
Echolight SpA, a med-tech company developing the first radiation-free bone densitometer for the early diagnosis of osteoporosis, is pleased to announce its entry into the Middle East market through a new strategic partnership with IHD MEA – International Healthcare Developers – with the task of establishing a reliable distribution sales network in the area to promote the innovative Echolight’s range of products. IHD MEA professional team will act as Echolight front office from Dubai to support local distributors and importers, to manage regulatory procedures, relationship with key opinion leaders, marketing activities and training & education programs.
The aim of the new partnership is motivated by the desire to be closer to customers, focusing first on UAE, Saudi Arabia, Iran and Egypt, then covering the entire Middle East and Africa markets. This is another decisive step in spreading EchoS, the breakthrough bone densitometer developed by Echolight, in emerging and promising markets to make it the new-state-of-the-art solution for the early diagnosis of osteoporosis.
About Echolight SpA
Echolight is a high-tech biomed company for the development of the very first radiation free bone densitometer for the early diagnosis of osteoporosis at lumbar vertebrae and femoral neck. The company is in compliance with the standard: UNI CEI EN ISO 13485:2012; ISO 13485:2003; UNI EN ISO 9001: 2008; CE Mark Medical Device. Echolight Headquarters is based at Ecotekne University Campus in Lecce, Italy.
About IHD MEA
IHD MEA is a platform formulated by dynamic professionals in healthcare industry. IHD MEA aims to transform manufactured technologies into successful business deals. We harvest across six territories GCC, Levant, Eastern Region, East Central Africa, North Africa and Turkey to identify and capitalize on growth opportunities. IHD MEA has representative offices in Dubai, Cairo, Dusseldorf and Prague.